INS and type 2 diabetes mellitus: A post hoc analysis of the insulin glargine (Lantus®) vs. insulin detemir (Levemir®) Treat-To-Target (L2T3) study, one of the RCTs included in this analysis, also demonstrated a similar relationship between final basal insulin dose (glargine or detemir) and the baseline characteristics of age, BMI, and FPG in patients with T2DM [28].